|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data have important implications for the treatment of CHB patients who fail to show an early response to Peg-IFNα-2a monotherapy.
|
28854883 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, only a minority of chronic hepatitis B (CHB) patients generate a sustained response after treatment with recombinant IFNα.
|
27839836 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, ss469415590 genotypes were not associated with response to PEG-IFN in Thai patients with HBeAg-positive and HBeAg-negative CHB.
|
26225703 |
2015 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
HBsAg is a strong predictor of response to PEG-IFN in HBeAg-positive CHB.
|
23553752 |
2013 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to investigate the role of retinoic acid-inducible gene-I (RIG-I) in prediction of IFN-α curative effect of CHB patients.
|
29790851 |
2018 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even after stimulation by TLR agonists, no change was found in IFN-α production in CHB patients.
|
27658394 |
2016 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of these features, new therapeutic trials based upon a combination of PEG-IFN and third generation NUC such as entecavir and tenofovir, in both naïve and NUC-exposed patients, are ongoing to further increase the rates of HBsAg seroclearance, which remains the 'ideal end-point' in all HBeAg-negative CHB subjects.
|
23286860 |
2013 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The highest response rate to IFN treatment was found in patients infected with HBV genotype A, followed by HBV genotypes B, C, and D. The long-term effect of IFN-α on CHB has not yet been elucidated.
|
25309065 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extended treatment with PEG IFNα-2a with lamivudine or adefovir for 96 weeks is a promising strategy to achieve high rates of sustainable HBeAg and HBsAg seroconversion and HBV DNA suppression in patients with HBeAg-positive CHB.
|
23615131 |
2013 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thirty CHB subjects on long-term treatment with tenofovir (TDF) and HBV suppression were enrolled and randomized 1:2 to either receive Peg-IFN-α-2a add-on therapy or continue TDF alone.
|
29091327 |
2018 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The level of NK cells was decreased in hepatitis B-associated liver cirrhosis significantly and had no changes in CHB or hepatocellular carcinoma, while the frequency of NK cells gradually decreased from the baseline to week 24 and then increased since week 24-48 in CHB with IFN-<i>α</i> treatment.
|
31158068 |
2019 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This retrospective analysis compared the treatment efficacy of PEG-IFN-α2b alone in 55 HBeAg-positive CHB patients with different baseline HBsAg levels.
|
25009392 |
2014 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data support that SNP rs7574865 is associated with response to PEG-IFN therapy in Thai patients with CHB, regardless of baseline HBeAg status.
|
31421662 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The response to lamivudine therapy shares with IFN a rapid decline in ALT accompanied by an improvement in histology; at variance with IFN, in HBeAg-positive chronic hepatitis B (CHB) there is delayed seroconversion to anti-HBe which accumulates over time, the switch to anti-HBs is more rare and in the long-term, the activity of the drug is abolished by the emergence of viral mutations (YMDD-motif mutants) that may rekindle the disease.
|
14521491 |
2003 |
|
Complete atrioventricular block
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of IFN-α/βR-2 in monocytes can be used as a predictable parameter to evaluate the effect of IFN-α treatment in CHB patients.
|
21445562 |
2011 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.
|
29456079 |
2018 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL28-B polymorphisms are related to different response in the treatment of CHB HBeAg-negative with PEG-IFN, and the E genotype is a novel negative predictive factor.
|
24316030 |
2014 |
|
Complete atrioventricular block
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, IFN-α boosted the expression of Mx2 and cytokine genes in γδT cells from CHB patients in vitro.
|
25774808 |
2015 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate the involvement of miR-548j in aberrant production of type I IFN in CHB patients, and provide a potential target for developing anti-HBV therapies.
|
28342861 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peginterferon alpha-2a (Peg-IFN α-2a) is a recommended international guideline for treatment of CHB children, which is limited to children aged > 3 years.
|
31487005 |
2019 |